NYSE:MED Medifast (MED) Stock Price, News & Analysis $19.02 -0.43 (-2.21%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$18.97▼$19.5350-Day Range$18.30▼$21.9652-Week Range$17.86▼$86.89Volume41,187 shsAverage Volume455,163 shsMarket Capitalization$208.08 millionP/E Ratio3.07Dividend YieldN/APrice Target$49.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medifast alerts: Email Address Medifast MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside155.8% Upside$49.75 Price TargetShort InterestHealthy26.01% of Float Sold ShortDividend StrengthN/ASustainability-4.00Upright™ Environmental ScoreNews Sentiment0.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth28.70%From $1.15 to $1.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsConsumer Staples Sector36th out of 132 stocksMiscellaneous Food Preparations & Kindred Products Industry1st out of 5 stocks 2.8 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted26.01% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Medifast has recently decreased by 6.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. Previous Next 2.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a -1.18% net impact score from Upright. The largest negative impact of Medifast in category "GHG emissions" seems to be driven mostly by its "Meal replacement soups", "Meal replacement bars", "Meal replacement drinks", and "Protein bars" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -4.00. Previous Next 2.2 News and Social Media Coverage News SentimentMedifast has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Medifast this week, compared to 3 articles on an average week.Search Interest7 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows6 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 28.70% in the coming year, from $1.15 to $1.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 3.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 3.14, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 22.45.Price to Book Value per Share RatioMedifast has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Medifast Stock (NYSE:MED)Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More MED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MED Stock News HeadlinesAugust 17, 2024 | uk.finance.yahoo.comMedifast Inc (MDF.MU)August 12, 2024 | finance.yahoo.comMedifast's (NYSE:MED) Soft Earnings Don't Show The Whole PictureAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 9, 2024 | bizjournals.comMedifast pivots again as revenue falls by 43%August 7, 2024 | finance.yahoo.comMedifast Second Quarter 2024 Earnings: Misses ExpectationsAugust 6, 2024 | seekingalpha.comMedifast, Inc. (MED) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | theglobeandmail.comMedifast (NYSE:MED) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock DropsAugust 6, 2024 | msn.comMedifast, Inc. (NYSE:MED) Q2 2024 Earnings Call TranscriptAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 6, 2024 | finanznachrichten.deMedifast Announces Second Quarter 2024 Financial ResultsAugust 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Consumer Cyclical Companies: Penn National Gaming (PENN), Lincoln Edu (LINC) and Medifast (MED)August 5, 2024 | investorplace.comMED Stock Earnings: Medifast Beats EPS, Beats Revenue for Q2 2024August 4, 2024 | markets.businessinsider.comHere's what Wall Street expects from Medifast's earnings reportAugust 4, 2024 | finance.yahoo.comMedifast (MED) Q2 Earnings: What To ExpectJuly 22, 2024 | businesswire.comMedifast to Announce Financial Results for the Second Quarter Ended June 30, 2024July 22, 2024 | investorplace.comTime to Unload: 3 Stocks in Deep Trouble to Sell NowJune 14, 2024 | investorplace.com3 Stocks to Sell as Ozempic Surges in PopularityJune 12, 2024 | investorplace.com7 Small-Cap Value Stocks Leaving the S&P 500 in the DustSee More Headlines Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today8/22/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$49.75 High Stock Price Target$82.00 Low Stock Price Target$17.50 Potential Upside/Downside+155.8%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$6.20 Trailing P/E Ratio3.14 Forward P/E Ratio16.91 P/E GrowthN/ANet Income$99.42 million Net Margins3.81% Pretax Margin4.84% Return on Equity25.77% Return on Assets17.04% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.46 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.20 Cash Flow$11.51 per share Price / Cash Flow1.69 Book Value$18.50 per share Price / Book1.05Miscellaneous Outstanding Shares10,940,000Free Float10,664,000Market Cap$212.78 million OptionableOptionable Beta1.15 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Daniel R. Chard (Age 59)Executive Chairman & CEO Comp: $1.94MMr. James P. Maloney CPA (Age 56)Chief Financial Officer Comp: $823.91kMr. Anthony E. Tyree (Age 59)Chief Business Operations Officer Comp: $655.86kMr. Jason L. Groves Esq. (Age 53)Executive VP, General Counsel & Corporate Secretary Comp: $669.51kMr. Nicholas M. Johnson (Age 44)Chief Field Operations Officer Comp: $696.4kMr. Jonathan Barrett MacKenzie (Age 52)VP of Finance & Chief Accounting Officer Mr. Steven ZenkerVice President of Investor RelationsMs. Claudia C. Greninger (Age 51)Chief Human Resources Officer More ExecutivesKey CompetitorsUSANA Health SciencesNYSE:USNANu Skin EnterprisesNYSE:NUSNature's Sunshine ProductsNASDAQ:NATRVeruNASDAQ:VERUEstée Lauder CompaniesNYSE:ELView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 800 shares on 8/16/2024Ownership: 0.000%Quarry LPBought 2,282 shares on 8/16/2024Ownership: 0.024%Millennium Management LLCBought 128,719 shares on 8/15/2024Ownership: 4.290%AQR Capital Management LLCBought 210,669 shares on 8/15/2024Ownership: 3.565%Cubist Systematic Strategies LLCSold 5,200 shares on 8/14/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $67.22 on January 1st, 2024. Since then, MED stock has decreased by 71.1% and is now trading at $19.45. View the best growth stocks for 2024 here. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) posted its quarterly earnings results on Monday, August, 5th. The specialty retailer reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.56. The specialty retailer earned $168.56 million during the quarter, compared to the consensus estimate of $160.44 million. Medifast had a net margin of 3.81% and a trailing twelve-month return on equity of 25.77%. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Medifast's major shareholders? Top institutional investors of Medifast include Renaissance Technologies LLC (8.76%), Millennium Management LLC (4.29%), AQR Capital Management LLC (3.57%) and Acadian Asset Management LLC (3.09%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ) and Intel (INTC). This page (NYSE:MED) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
